Home
SCIO Path to Approval
Early Clinical Research
Strategy and TPP
Translational Medicine and Epigenetics
Biologics, Cell and Gene Therapy
Real World Evidence
Repurposing
Orphan Drug Solutions
Biomarkers and Surrogate Endpoints
Regulatory Affairs FDA and EMA
Medical Affairs and Clinical Research
Due Diligence
Trial Management & Trial Rescue
People
Senior Advisors
Candida Fratazzi
Claudio Carini
Federico Goodsaid
Our Clients
Our Collaborators
Testimonials
Resources
BBCR Voice
Case Studies
Published Studies
Conferences & Presentations
Job Opportunities
Contact Info
Select Page
Industry News
Biotech Industry News
Inventor of the PCR, Kary Mullis, Dies
August 15th, 2019 | Industry News
The cost of Trial Failure- ImmusanT Celiac Drug Trial Failure ‘Devastating’
July 2nd, 2019 | Industry News
Newer posts »
Search for:
Categories
Biomarkers & Surrogate Endpoints
Company News
Drug Development
Due Diligence
Early Clinical Development
Industry News
Medical Affairs and Clinical Research
Miscellaneous
Orphan Diseases
Pre-IND
Precision Medicine
Rare Disease
Real World Evidence
Regulatory
Regulatory Affairs
Strategy and TPP
Translation Medicine and Epigenetics
Trial Management
Trial Rescue
Recent Posts
Building a Stronger Path to Market Through Early Clinical Research Strategy
Why Early Clinical Research Strategy Is Critical to Successful Drug Development
Why Rare Disease Drug Development Requires a Different Clinical Strategy
Why do orphan drug launches require specialized strategic planning?
BBCR and its consultants are dedicated to advancing innovative and repurposed treatments for orphan diseases, an area where impact is high, but the path is complex.
